Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.

Eline van OverbeekeBirgit De BeleyrJan de HoonRene WesthovensIsabelle Huys

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2018)

Our study showed that rheumatologists, more so than patients, were convinced that there can be differences between originators and biosimilars. Despite safety being the major concern of patients, patients trusted their physician's decision to start on or switch to a biosimilar. The evolution of the uptake of biosimilars in Belgium might thus depend mainly on the perception of physicians.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
primary care
rheumatoid arthritis patients
prognostic factors
decision making